Silexion reports SIL204 shows up to 99.7% inhibition across 11 human cell lines, first gastric cancer data

Silexion Therapeutics Corp

SIL204 achieved 83.5% to 99.7% inhibition at nanomolar concentrations (IC50 23.4–85.3 nM) in 11 lines from 5 cancer types.
Highest activity: 99.7% inhibition in NCIH2009 lung cells (G12A mutation); first gastric cancer data showed 89.2% inhibition (G12D).
Pancreatic G12R (17% of cases) showed 91.5% inhibition (IC50 31.5 nM) in KP2 cells; expanded colorectal validation in HCT 116 (G13D).
SIL204 now confirmed active against G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations.
Phase 2/3 trial planned H1 2026; regulatory submissions to Israel MoH in Q4 2025 and EU in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.